Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (49.5), the stock would be worth ¥274.1 (0% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 49.3 | ¥273 |
0%
|
| 3-Year Average | 49.5 | ¥274.1 |
+0%
|
| 5-Year Average | 49.5 | ¥274.1 |
+0%
|
| Industry Average | 3.5 | ¥19.31 |
-93%
|
| Country Average | 3.3 | ¥18.27 |
-93%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
¥116.6B
|
/ |
Oct 2025
¥2.2B
|
= |
|
|
¥116.6B
|
/ |
Dec 2025
¥2.2B
|
= |
|
|
¥116.6B
|
/ |
Dec 2026
¥2.1B
|
= |
|
|
¥116.6B
|
/ |
Dec 2027
¥2.6B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
112.7B CNY | 49.3 | -132.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 12.8 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 5.9 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 5.1 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 5.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 4.7 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 3.2 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 3.1 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 3.3 |
| 70th Percentile | 6.2 |
| Max | 5 034 353.9 |
Other Multiples
Sichuan Biokin Pharmaceutical Co Ltd
Glance View
Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.